RxDoctor Payments Data

Christine Stamatos

Adult Health · Babylon, NYNPI 1336387083

Payments from drug & device makers

$9,642in general payments, 2019–2025

Across 25 payments — averaging $385.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tonix Medicines, Inc.$9K
  • Amgen$183
  • UCB, Inc.$101
  • Johnson & Johnson$35
  • Bioxcel Therapeutics, Inc.$26

What the payments were for

  • Consulting fees$8,13884%
  • Travel & lodging$7217%
  • Food & beverage$6717%
  • Education$1121%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Tonix Medicines, Inc.8$9,297
Amgen(2 entities)14$183
UCB, Inc.1$101
Johnson & Johnson1$35
Bioxcel Therapeutics, Inc.1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,642 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$1,021,207
Medicare patients
311
Services billed
61,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab48$410,527
StelaraUstekinumab15$354,534
Enbrel SureclickEtanercept14$212,611
Cimzia (2 Pack)Certolizumab Pegol20$125,449
Orencia ClickjectAbatacept17$121,071
Xeljanz XrTofacitinib Citrate16$86,107
TymlosAbaloparatide28$85,860
BenlystaBelimumab14$85,467
KevzaraSarilumab14$57,542
Teriparatide21$48,644
ProliaDenosumab15$24,636
RasuvoMethotrexate/Pf42$23,434
OtrexupMethotrexate/Pf14$10,330
Leflunomide69$8,307
Hydroxychloroquine Sulfate152$7,948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$35$354,53415 claims
UCB, Inc.Cimzia (2 Pack)$101$125,44920 claims
AmgenProlia$183$24,63615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.

Other adult health in Babylon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →